

Renal Biomarkers: Technologies and Global Markets

https://marketpublishers.com/r/RCF1ED15AB23EN.html

Date: December 2022

Pages: 93

Price: US\$ 5,500.00 (Single User License)

ID: RCF1ED15AB23EN

Abstracts

Report Scope:

This report incorporates an in-depth analysis of the renal biomarker market, including market estimations and trends through 2021. Major players, competitive intelligence, innovative technologies, market dynamics and regional opportunities are discussed in detail. The report examines recent developments and product portfolios of major players. The patent analysis focuses on technological trends in recent years in regions such as the U.S., Europe, and Japan. The report presents a market analysis and estimates the CAGR for renal biomarkers.

The scope of the report extends only to renal biomarker consumables and not devices used to study renal biomarkers. All types of renal biomarkers have been considered in research, clinical trials and for diagnostic purposes.

This report segments the global market by these geographic regions: North America, Europe, Asia-Pacific, and the Rest of the World (RoW) region. For market estimates, data is provided for 2021 as the base year, 2022 and forecast through year-end 2027.

Report Includes:

41 data tables and 24 additional tables

A detailed overview and up-to-date analysis of the global markets for renal biomarkers

Analyses of the global market trends, with market revenue data for 2019-2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027

Renal Biomarkers: Technologies and Global Markets



Estimation of the actual market size and revenue forecast for renal biomarkers market, and corresponding market share analysis by assay type, application, end user, and region

Updated information on market drivers and opportunities for renal biomarkers, key shifts, regulations and industry specific challenges, and other demographic factors that will shape the market demand over the coming years (2022-2027)

Identification of the companies best positioned to meet the demand owing to their proprietary technologies, product launches, mergers and acquisitions, and other market strategic advantages

Review of recent industry structure for biomarkers, R&D activities, and analysis of the competitive landscape based on recent developments and segmental revenues

Patent activity and review of patent grants for biomarkers and related technologies

Descriptive company profiles of the market leading players, including BioMerieux, Gentian Diagnostic, Proteomics International, Thermo Fisher Scientific, SphingoTec, and BioPorto



Contents

CHAPTER 1 INTRODUCTION

- 1.1 Study Goals and Objectives
- 1.2 Reasons for Doing this Study
- 1.3 What's New in this Report
- 1.4 Scope of Report
- 1.5 Information Sources
- 1.6 Methodology
- 1.7 Geographic Breakdown
- 1.8 Analyst's Credentials
- 1.9 BCC Custom Research
- 1.10 Related BCC Research Reports

CHAPTER 2 SUMMARY AND HIGHLIGHTS

CHAPTER 3 MARKET OVERVIEW

- 3.1 Introduction
 - 3.1.1 Kidneys
 - 3.1.2 Renal Biomarkers
 - 3.1.3 Definition
- 3.2 Market Dynamics
 - 3.2.1 Drivers
 - 3.2.2 Restraints
 - 3.2.3 Opportunities
- 3.3 Regulatory Process for Biomarkers
 - 3.3.1 European Medicines Agency
 - 3.3.2 Biomarkers Qualified by the FDA

CHAPTER 4 IMPACT OF COVID-19 PANDEMIC

- 4.1 Impact of COVID-19 on Renal Biomarker Market
 - 4.1.1 Increased Incidence of AKI
 - 4.1.2 Other Diseases
- 4.2 Chronic Dialysis Patients
 - 4.2.1 Kidney Transplant Recipients



CHAPTER 5 GLOBAL RENAL BIOMARKER MARKET BY TYPE

- 5.1 Overview
- 5.2 Filtered Renal Biomarkers (Impaired Tubular Reabsorption)
 - 5.2.1 Albumin
 - 5.2.2 Cystatin C
 - 5.2.3 Beta-2 Microglobulin
- 5.3 Upregulated Biomarkers
 - 5.3.1 KIM-1 Kidney Injury Molecule
 - 5.3.2 Neutrophil Gelatinase Associated Lipocalin
 - 5.3.3 Clusterin
 - 5.3.4 Interleukin-18
 - 5.3.5 Netrin-1
- 5.4 Preformed
 - 5.4.1 Alkaline Phosphatase
 - 5.4.2 Gamma-Glutamyl Transpeptidase
 - 5.4.3 Glutathione S-Transferase
 - 5.4.4 N-acetyl-?-D Glucosaminidase
 - 5.4.5 Liver-Type Fatty Acid-Binding Protein
- 5.4.6 Tissue Inhibitor of Metalloprotease-2 and Insulin-Like Growth Factor-binding Protein
- 5.5 Other Biomarkers
 - 5.5.1 Blood Urea Nitrogen
 - 5.5.2 Serum Creatinine
 - 5.5.3 Downregulated

CHAPTER 6 GLOBAL MARKET FOR RENAL BIOMARKERS BY REGION

- 6.1 North America
 - 6.1.1 United States
 - 6.1.2 Canada
- 6.2 Europe
 - 6.2.1 Germany
 - 6.2.2 Italy
 - 6.2.3 France
 - 6.2.4 Spain
 - 6.2.5 United Kingdom
 - 6.2.6 Rest of Europe
- 6.3 Asia-Pacific



- 6.3.1 Australia
- 6.3.2 Japan
- 6.3.3 China
- 6.3.4 Rest of Asia
- 6.4 Rest of the World

CHAPTER 7 RENAL BIOMARKER MARKET BY END USER

- 7.1 Hospitals
- 7.2 Research Centers
- 7.3 Other End Users

CHAPTER 8 RENAL BIOMARKER MARKET BY TECHNIQUE

- 8.1 Overview
- 8.2 Enzyme Linked Immunosorbent Assay
- 8.3 Particle-Enhanced Turbidimetric Immunoassays
- 8.4 Colorimetric Assays
- 8.5 Chemiluminescent Enzyme Immunoassays
- 8.6 Other Detection Methods

CHAPTER 9 COMPETITIVE LANDSCAPE

CHAPTER 10 COMPANY PROFILES

ABBOTT LABORATORIES

BECKMAN COULTER INC.

BIOMERIEUX

BIOPORTO A/S

BIO-RAD

ENZO BIOCHEM INC.

GENTIAN DIAGNOSTIC AB

HYTEST LTD.

NEPHROSANT

Nexelis

PROTEOMICS INTERNATIONAL LABORATORIES LTD.

RANDOX LABORATORIES LTD.

ROCHE (F. HOFFMANN-LA ROCHE AG)

SPHINGOTEC

Renal Biomarkers: Technologies and Global Markets



THERMO FISHER SCIENTIFIC

CHAPTER 11 PATENT REVIEW

CHAPTER 12 CLINICAL TRIAL ANALYSIS



List Of Tables

LIST OF TABLES

Summary Table: Global Market for Renal Biomarkers, by Segment, Through 2027

Table 1: Applications for Biomarkers, with Examples

Table 2: Changes in Aging Kidneys

Table 3: Qualified Biomarkers of EMA SAWP/CHMP, as of March 30, 2020

Table 4: Stages in the FDA Biomarker Qualification Program

Table 5: Qualified Biomarkers for FDA CDER BQP, as of Feb. 19, 2020

Table 6: Cases of COVID-19 and Related Deaths, by Country, as of October 2022

Table 7: Effects of COVID-19 on Kidney Disease Patients

Table 8: Properties of KIM-1

Table 9: Global Market for Renal Biomarkers, by Region, Through 2027

Table 10: AKI in Developed and Developing Countries

Table 11: North American Market for Renal Biomarkers, by Country, Through 2027

Table 12: North American Market for Renal Biomarkers, by Type, Through 2027

Table 13: U.S. Market for Renal Biomarkers, by Type, Through 2027

Table 14: Canadian Market for Renal Biomarkers, by Type, Through 2027

Table 15: European Kidney Health Alliance Recommendations

Table 16: European Market for Renal Biomarkers, by Region, Through 2027

Table 17: European Market for Renal Biomarkers, by Type, Through 2027

Table 18: German Market for Renal Biomarkers, by Type, Through 2027

Table 19: Italian Market for Renal Biomarkers, by Type, Through 2027

Table 20: French Market for Renal Biomarkers, by Type, Through 2027

Table 21: Spanish Market for Renal Biomarkers, by Type, Through 2027

Table 22: U.K. Market for Renal Biomarkers, by Type, Through 2027

Table 23: Rest of Europe Market for Renal Biomarkers, by Type, Through 2027

Table 24: Asia-Pacific Market for Renal Biomarkers, by Country, Through 2027

Table 25: Asia-Pacific Market for Renal Biomarkers, by Type, Through 2027

Table 26: Australian Market for Renal Biomarkers, by Type, Through 2027

Table 27: Japanese Market for Renal Biomarkers, by Type, Through 2027

Table 28: Chinese Market for Renal Biomarkers, by Type, Through 2027

Table 29: Rest of Asia Market for Renal Biomarkers, by Type, Through 2027

Table 30: RoW Market for Renal Biomarkers, by Type, Through 2027

Table 31: Global Market for Renal Biomarkers, by End User, Through 2027

Table 32: Global Market for Renal Biomarkers, by Technique, Through 2027

Table 33: Methods for Detection of Renal Biomarkers

Table 34: Company Developments, 2019-2022



- Table 35: Abbott Laboratories: Renal Biomarker Portfolio
- Table 36: Abbott Laboratories: Revenue and R&D Expenses, 2019 to 2021
- Table 37: Abbott Laboratories: Revenue, by Segment
- Table 38: BioMerieux: Revenue and R&D Expenditure, 2019-2021
- Table 39: BioMerieux: Revenue of Immunoassay Segment, 2019-2021
- Table 40: BioMerieux: Recent Developments, 2019-2022
- Table 41: Bioporto: Revenue and R&D Expense, 2019-2021
- Table 42: Bioporto: NGAL Revenue, 2019-2021
- Table 43: Bioporto: Recent Developments, 2019-2022
- Table 44: Bio-Rad: Kidney Toxicity Assay Portfolio
- Table 45: Bio-Rad: Revenue and R&D Expense, 2019-2021
- Table 46: Enzo Biochem: Revenue and R&D Expenses, 2019-2021
- Table 47: Enzo Biochem: Revenue, by Segment, 2019-2021
- Table 48: Enzo Biochem: Revenue, by Region, 2019 to 2021
- Table 49: Gentian Diagnostic: Revenue, by Region, 2019-2021
- Table 50: Gentian Diagnostic: Recent Developments, 2019-2022
- Table 51: Nexelis: Recent Developments, 2019-2022
- Table 52: Nexelis: Renal Biomarker Portfolio
- Table 53: Proteomics International: Revenue, 2019-2022
- Table 54: Proteomics: Recent Developments, 2019-2022
- Table 55: Roche: Revenue and R&D Expenses, 2019-2021
- Table 56: Roche: Revenue, by Segment, 2019-2021
- Table 57: Roche: Revenue, by Diagnostic Segment, 2019-2021
- Table 58: Roche: Revenue, by Region, 2019 to 2022
- Table 59: Sphingotec: Recent Developments, 2019-2022
- Table 60: Thermo Fisher Scientific: Revenue and R&D Expenses, 2019-2021
- Table 61: Thermo Fisher Scientific: Revenue, by Segment, 2019-2021
- Table 62: Thermo Fisher Scientific: Recent Developments, 2019-2022
- Table 63: Precision Medicine Patent Criteria in U.S. and Europe
- Table 64: List of Renal Biomarker Patents



List Of Figures

LIST OF FIGURES

Summary Figure: Global Market for Renal Biomarkers, by Type, 2019-2027

Figure 1: Applications for Biomarkers

Figure 2: Timeline for Renal Biomarkers

Figure 3: Initial Timeline of EMA Biomarker Qualification

Figure 4: Flowchart of EMA Biomarker Qualification Process

Figure 5: Steps in EMA Biomarker Qualification

Figure 6: Steps in Biomarker Quantification

Figure 7: Pathways for Excretion of IGFBP7 and TIMP-2

Figure 8: Percentage of CKD Patients, by Age, in U.S.

Figure 9: Number of Patients Receiving Kidney Dialysis in Canada

Figure 10: EU Patients Undergoing Kidney Dialysis and Transplants

Figure 11: Shares of Leading Companies in the Renal Biomarker Market

Figure 12: Clinical Trials of Renal Biomarkers, by Therapeutic Area, 2019 to October

2022

Figure 13: Clinical Trials of Renal Biomarkers, by Sponsor

Figure 14: Clinical Trials of Renal Biomarkers, by Location



I would like to order

Product name: Renal Biomarkers: Technologies and Global Markets

Product link: https://marketpublishers.com/r/RCF1ED15AB23EN.html

Price: US\$ 5,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/RCF1ED15AB23EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970